Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

Prior treatment

• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.

Other illness

• Prior invasive malignancy, except non-melanoma skin cancer, unless disease free for a minimum of 3 years
• History of underlying liver disease, including but not limited to cirrhosis, hepatitis or hemochromatosis
• History of major liver resection
• Severe, active co-morbidity, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
• Absolute contraindication to cisplatin including severe hypersensitivity

Other

• Variants of unknown significance (VUS) in core or non-core HR genes will be excluded
• Clinical ascites.
• Single right kidney. (A single left kidney is allowed)
• Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.

• Histologically or cytologically confirmed adenocarcinoma of the pancreas metastatic to the liver (liver metastases confirmed pathologically or radiographic liver lesions most consistent with metastases in a patient with pathologically proven pancreatic adenocarcinoma)
• Germline or biallelic somatic pathogenic mutations in the core HR genes including BRCA1, BRCA2, PALB2 and ATM genes are required for dose escalating cohort. Pathogenic germline or biallelic somatic alterations in other HR genes including (BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) are allowed in the expansion cohort. Confirmation of the required mutations can be from MSK IMPACT or any other approved germline genetic testing for eligibility purposes.
• ≥1 liver lesion(s) measurable on a contrast-enhanced liver CT, MRI or PET/CT performed within 6 weeks prior to study entry. Any tumor location within the liver is allowed
• At least 1 liver metastasis measuring ≤ 7 cm
• Extrahepatic disease outside the liver is permitted if the hepatic disease is judged to be life-limiting (1-2 sites of disease are allowed, including lung and non-regional nodes, up to and including 5 individual lesions)
• Age ≥18
• ECOG 0-2
• Any prior chemotherapy therapy is allowed including prior treatment with platinum containing chemotherapy and irrespective of response to prior therapy
• Prior treatment with FDA-approved or investigational biologics or novel molecularly targeted therapies, including oral or IV formulations, are permitted. Patients must be off prior targeted therapy for at least 14 days or 4 half-lives prior to the initiation of the study treatment
• Use of an effective means of contraception in men and women of child-bearing potential
• Adequate organ and marrow function within 14 days prior to study entry, defined as:
• Absolute neutrophil count (ANC)\>1000/mm3
• Hemoglobin \>9 gm/dl (Note: The use of transfusion or other intervention to achieve Hgb \> 9.0 g/dl is acceptable.)
• Platelets \>100,000/mm3
• Serum creatinine \<1.5 mg/dl OR creatinine clearance of \>50 cc/min
• Total bilirubin \< 1.8 mg/dL
• Prothrombin time/INR \< 1.7
• Albumin ≥ 28 g/L
• AST and ALT \< 3 times ULN
• ALP \< 2.5 times ULN